Cantor Fitzgerald Downgrades Endo Pharmaceuticals (ENDP) to Hold; Sidelined Ahead of Lidoderm Decision; M&A Unlikely N-T
Tweet Send to a FriendGet Alerts ENDP Hot Sheet
Price: $38.82 --0%
Rating Summary:
8 Buy, 9 Hold, 6 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 3 | Down: 3 | New: 4
Rating Summary:
8 Buy, 9 Hold, 6 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 3 | Down: 3 | New: 4
Trade ENDP Now!
Cantor Fitzgerald downgraded Endo Pharmaceuticals (NASDAQ: ENDP) to Hold with a price target of $39.00.
Analyst, Irina Rivkind, said, "Mediocre quarter as Endo recovers from a supply disruption...We are moving to the sidelines in front of a Lidoderm decision...We don't discount the intrinsic value in the business: In the current M&A environment, Endo should not be overlooked as a potential takeout target. However, we view this possibility as unlikely in the near-term since we believe that management is focused on strengthening the business via integration and debt service. We lowered our 2012 numbers below guidance to account for lower revenue expectations in generics and device, coupled with higher SG&A expenses. We want to see more execution and integration before getting more positive on the stock."
For an analyst ratings summary and ratings history on Endo Pharmaceuticals click here. For more ratings news on Endo Pharmaceuticals click here.
Shares of Endo Pharmaceuticals closed at $34.66 yesterday, with a 52 week range of $26.02-$42.79.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
Analyst, Irina Rivkind, said, "Mediocre quarter as Endo recovers from a supply disruption...We are moving to the sidelines in front of a Lidoderm decision...We don't discount the intrinsic value in the business: In the current M&A environment, Endo should not be overlooked as a potential takeout target. However, we view this possibility as unlikely in the near-term since we believe that management is focused on strengthening the business via integration and debt service. We lowered our 2012 numbers below guidance to account for lower revenue expectations in generics and device, coupled with higher SG&A expenses. We want to see more execution and integration before getting more positive on the stock."
For an analyst ratings summary and ratings history on Endo Pharmaceuticals click here. For more ratings news on Endo Pharmaceuticals click here.
Shares of Endo Pharmaceuticals closed at $34.66 yesterday, with a 52 week range of $26.02-$42.79.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- Morgan Stanley Maintains Bullish Stance on Walter Energy (WLT)
- Barclays Downgrades CYS Investments (CYS) to Equalweight
- Barclays Downgrades Javelin Mortgage (JMI) to Underweight
Create E-mail Alert Related Categories
DowngradesRelated Entities
Cantor Fitzgerald
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
